On the basis of the potential activated pathway in the MSL subgroup, we treated BT-20 and HCC-38 cells with CSC-related inhibitors such as hedgehog inhibitor vismodegib (41), NF-κB pathway inhibitor bortezomib (42), and PI3K inhibitor LY294002 (43). The gene discussed is NFKB1; the disease is hepatocellular carcinoma.